MedTrace Logo

GUIDING MULTI-MODAL THERAPIES AGAINST MINIMAL RESIDUAL DISEASE BY LIQUID BIOPSIES

NCT06102889 · Status: ENROLLING_BY_INVITATION · Type: OBSERVATIONAL · Enrollment: 200

Last updated 2024-04-24

No results posted yet for this study

Summary

The overall objective of this study is to confirm that ctDNA detected after curative intended treatment for PDAC is a marker of residual disease and for risk-of-recurrence, and applicable in clinical practice.

Primary objective To confirm that ctDNA analyses performed after PDAC treatment can identify patients with a high risk-of-recurrence.

Specifically, we want to determine the association between disease-free survival (DFS) and ctDNA detection status after (1) curative-intended surgery and (2) adjuvant chemotherapy.

Conditions

  • Pancreatic Adenocarcinoma

Interventions

DIAGNOSTIC_TEST

liquid biopsy

Taking blood samples (liquid biopsy) for multiple analysis in genomics, proteomics, and metabolomics

Sponsors & Collaborators

  • Universitätsklinikum Hamburg-Eppendorf

    collaborator OTHER

  • Aarhus University Hospital

    collaborator OTHER

  • Centre Hospitalier Universitaire de Nice

    collaborator OTHER

  • Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III

    collaborator OTHER

  • Medical University of Graz

    collaborator OTHER

  • Centre Hospitalier Régional Universitaire Montpellier

    collaborator OTHER

  • Karolinska University Hospital

    lead OTHER

Principal Investigators

  • Claus Lindbjerg Andersen, MD · Aarhus University Hospitsl

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-05-02
Primary Completion
2025-12-31
Completion
2026-12-31

Countries

  • Sweden

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06102889 on ClinicalTrials.gov